Treatment of ER+/PR+/HER2- Breast Cancer in Elderly Patients

Initial Assessment and Surgical Options

For patients with bilateral invasive breast cancer that is ER+/PR+/HER2-, the National Comprehensive Cancer Network recommends surgical options including breast-conserving surgery with sentinel lymph node biopsy or mastectomy with sentinel lymph node biopsy, depending on tumor size, location, and patient preference 1, 2
The American Cancer Society suggests that if breast-conserving surgery is chosen, postoperative radiation therapy is strongly recommended to reduce local recurrence risk 2, 3

The European Society for Medical Oncology recommends that for postmenopausal women with ER+/PR+/HER2- breast cancer, endocrine therapy is the cornerstone of treatment 4, 5
The American Society of Clinical Oncology suggests that aromatase inhibitors are preferred over tamoxifen in this age group as they have shown superior response rates and time to progression 4, 5
The National Comprehensive Cancer Network recommends that the duration of endocrine therapy should be at least 5 years 2, 4

The National Comprehensive Cancer Network suggests that in elderly patients with ER+/PR+/HER2- disease, the absolute benefit of adding chemotherapy to endocrine therapy may be small and should be weighed against potential toxicity 6, 7
The American Society of Clinical Oncology recommends that factors that would favor chemotherapy include higher tumor grade, larger tumor size, or lymph node involvement 7
The European Society for Medical Oncology suggests that if lymph nodes are positive, adjuvant chemotherapy should be more strongly considered despite the patient's age 8, 3

The American Society for Radiation Oncology recommends that after breast-conserving surgery, radiation therapy to the whole breast is generally recommended 2, 3
The National Comprehensive Cancer Network suggests that post-mastectomy radiation therapy is indicated if there are 4 or more positive axillary lymph nodes 8, 3

The International Society of Geriatric Oncology recommends that treatment decisions should consider the patient's physiological age rather than chronological age 7
The National Osteoporosis Foundation suggests that bone health monitoring is important for women on aromatase inhibitors, with bone mineral density determination at baseline and periodically thereafter 6

The National Comprehensive Cancer Network recommends clinical follow-up every 4-6 months for the first 5 years, then annually 6
The American Cancer Society suggests annual mammography 6
The American Society of Clinical Oncology recommends regular assessment of adherence to endocrine therapy and monitoring for side effects of endocrine therapy, particularly bone health in patients on aromatase inhibitors 6